Liang Chen

Dr. Liang Chen


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2016 in European Radiology
Verified
Journal Article
Closed access
PDF file
JYJinhua Yu
Jinhua Yu
ZSZhifeng Shi
Zhifeng Shi
YLYuxi Lian
Yuxi Lian
ZLZeju Li
Zeju Li
TLTongtong Liu
Tongtong Liu
YMYing Mao
Ying Mao

1 December 2018 in NeuroImage
Verified
Journal Article
Closed access
GLGuangye Li
Guangye Li
SJShize Jiang
Shize Jiang
SPSivylla E. Paraskevopoulou
Sivylla E. Paraskevopoulou
MWMeng Wang
Meng Wang
YXYang Xu
Yang Xu
GSGerwin Schalk
Gerwin Schalk

8 September 2021 in Light: Science & Applications
Verified
Journal Article
Open access
PDF file
LTLechan Tao
Lechan Tao
QLQi Liu
Qi Liu
FZFuli Zhang
Fuli Zhang
YFYuting Fu
Yuting Fu
XZXi Zhu
Xi Zhu
XWXunbin Wei
Xunbin Wei
Photobiomodulation, by utilizing low-power light in the visible and near-infrared spectra to trigger biological responses in cells and tissues, has been considered as a possible therapeutic strategy for Alzheimer’s disease (AD), while its specific mechanisms have remained elusive. Here, we demonstrate that cognitive and memory impairment in an AD mouse model can be ameliorated by 1070-nm light via reducing cerebral β-amyloid (Aβ) burden, the hallmark of AD. The glial cells, including microglia and astrocytes, play important roles in Aβ clearance. Our results show that 1070-nm light pulsed at 10 Hz triggers microglia rather than astrocyte responses in AD mice. The 1070-nm light-induced microglia responses with alteration in morphology and increased colocalization with Aβ are sufficient to reduce Aβ load in AD mice. Moreover, 1070-nm light pulsed at 10 Hz can reduce perivascular microglia and promote angiogenesis to further enhance Aβ clearance. Our study confirms the important roles of microglia and cerebral vessels in the use of 1070-nm light for the treatment of AD mice and provides a framework for developing a novel therapeutic approach for AD.

10 November 2020 in Advanced Materials
Verified
Journal Article
Closed access
PDF file
MLMengwei Liu
Mengwei Liu
YZYujia Zhang
Yujia Zhang
KLKeyin Liu
Keyin Liu
GZGai Zhang
Gai Zhang
YMYing Mao
Ying Mao
TTTiger H. Tao
Tiger H. Tao

13 September 2023 in Advanced Science
Verified
Journal Article
Open access
CCChengwei Chen
Chengwei Chen
YBYuting Bao
Yuting Bao
LXLu Xing
Lu Xing
CJChengyong Jiang
Chengyong Jiang
YGYu Guo
Yu Guo
YMYing Mao
Ying Mao
Near‐infrared photobiomodulation has been identified as a potential strategy for Alzheimer's disease (AD). However, the mechanisms underlying this therapeutic effect remain poorly characterize. Herein, it is illustrate that 1070‐nm light induces the morphological alteration of microglia from an M1 to M2 phenotype that secretes exosomes, which alleviates the β‐amyloid burden to improve cognitive function by ameliorating neuroinflammation and promoting neuronal dendritic spine plasticity. The results show that 4 J cm−2 1070‐nm light at a 10‐Hz frequency prompts microglia with an M1 inflammatory type to switch to an M2 anti‐inflammatory type. This induces secretion of M2 microglial‐derived exosomes containing miR‐7670‐3p, which targets activating transcription factor 6 (ATF6) during endoplasmic reticulum (ER) stress. Moreover, it is found that miR‐7670‐3p reduces ATF6 expression to further ameliorate ER stress, thus attenuating the inflammatory response and protecting dendritic spine integrity of neurons in the cortex and hippocampus of 5xFAD mice, ultimately leading to improvements in cognitive function. This study highlights the critical role of exosomes derive from 1070‐nm light‐modulated microglia in treating AD mice, which may provide a theoretical basis for the treatment of AD with the use of near‐infrared photobiomodulation.

1 January 2018 in Theranostics
Verified
Journal Article
Open access
XGXihui Gao
Xihui Gao
QYQi Yue
Qi Yue
YLYikang Liu
Yikang Liu
DFDandan Fan
Dandan Fan
KFKun Fan
Kun Fan
CLCong Li
Cong Li
Blood-brain barrier (BBB) disruption is frequently observed in the glioma region. However, the tumor uptake of drugs is still too low to meet the threshold of therapeutic purpose.